Open Access. Powered by Scholars. Published by Universities.®
Biomedical Engineering and Bioengineering Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Biomedical Engineering and Bioengineering
Ionizable Lipid Nanoparticles For In Utero Mrna Delivery., Rachel S. Riley, Meghana V Kashyap, Margaret M Billingsley, Brandon White, Mohamad-Gabriel Alameh, Sourav K Bose, Philip W Zoltick, Hiaying Li, Rui Zhang, Andrew Y Cheng, Drew Weissman, William H Peranteau, Michael J Mitchell
Ionizable Lipid Nanoparticles For In Utero Mrna Delivery., Rachel S. Riley, Meghana V Kashyap, Margaret M Billingsley, Brandon White, Mohamad-Gabriel Alameh, Sourav K Bose, Philip W Zoltick, Hiaying Li, Rui Zhang, Andrew Y Cheng, Drew Weissman, William H Peranteau, Michael J Mitchell
Henry M. Rowan College of Engineering Faculty Scholarship
Clinical advances enable the prenatal diagnosis of genetic diseases that are candidates for gene and enzyme therapies such as messenger RNA (mRNA)-mediated protein replacement. Prenatal mRNA therapies can treat disease before the onset of irreversible pathology with high therapeutic efficacy and safety due to the small fetal size, immature immune system, and abundance of progenitor cells. However, the development of nonviral platforms for prenatal delivery is nascent. We developed a library of ionizable lipid nanoparticles (LNPs) for in utero mRNA delivery to mouse fetuses. We screened LNPs for luciferase mRNA delivery and identified formulations that accumulate within fetal livers, lungs, …
Antibody-Nanoparticle Conjugates To Enhance The Sensitivity Of Elisa-Based Detection Methods., Margaret M Billingsley, Rachel S. Riley, Emily S Day
Antibody-Nanoparticle Conjugates To Enhance The Sensitivity Of Elisa-Based Detection Methods., Margaret M Billingsley, Rachel S. Riley, Emily S Day
Henry M. Rowan College of Engineering Faculty Scholarship
Accurate antigen detection is imperative for clinicians to diagnose disease, assess treatment success, and predict patient prognosis. The most common technique used for the detection of disease-associated biomarkers is the enzyme linked immunosorbent assay (ELISA). In an ELISA, primary antibodies are incubated with biological samples containing the biomarker of interest. Then, detectible secondary antibodies conjugated with horseradish peroxidase (HRP) bind the primary antibodies. Upon addition of a color-changing substrate, the samples provide a colorimetric signal that directly correlates to the targeted biomarker concentration. While ELISAs are effective for analyzing samples with high biomarker content, they lack the sensitivity required to …